









Markets
/
Stocks
/
nasdaq-ipsc
/

Century Therapeutics Inc

IPSC

0.477USD

-0.030-5.88%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

41.19MMarket Cap

LossP/E TTM



Century Therapeutics Inc

0.477

-0.030-5.88%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

104 / 506

Overall Ranking

205 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.000

Target Price

+886.19%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.74% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 6.59M.

Fairly Valued

The company’s latest PE is -1.72, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 65.43M shares, decreasing 16.30% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.11M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.49.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.26, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 4.27%.

Score

Industry at a Glance

Previous score

8.26

Change



Financials

7.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.70

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.83, which is -66.36% below the recent high of -0.62 and -10.06% above the recent low of -2.01.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Century Therapeutics Inc is 6.00, with a high of 8.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.000

Target Price

+947.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Century Therapeutics Inc

IPSC

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.96, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 0.56 and the support level at 0.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.96

Change

-0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.002

Neutral

RSI(14)

39.897

Neutral

STOCH(KDJ)(9,3,3)

26.991

Sell

ATR(14)

0.026

Low Volatility

CCI(14)

-53.219

Neutral

Williams %R

72.586

Sell

TRIX(12,20)

-0.360

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.493

Sell

MA10

0.500

Sell

MA20

0.500

Sell

MA50

0.541

Sell

MA100

0.552

Sell

MA200

0.677

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 75.94%, representing a quarter-over-quarter decrease of 11.17%. The largest institutional shareholder is The Vanguard, holding a total of 2.11M shares, representing 2.44% of shares outstanding, with 12.80% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bayer AG

12.68M

Versant Ventures

12.17M

+6.24%

Fujifilm Holdings Corp

6.96M

Bain Capital Life Sciences Investors, LLC

5.41M

The Vanguard Group, Inc.

Star Investors

2.38M

-0.18%

Renaissance Technologies LLC

Star Investors

1.19M

-1.46%

Dafna Capital Management, LLC

1.70M

Casdin Capital, LLC

3.21M

-38.11%

Syncona Portfolio Ltd

1.21M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.04, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.78. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.